List of Excipients in Branded Drug NITROGEN OXYGEN MIX

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Airgas Usa LLC	NITROGEN OXYGEN MIX	nitrogen oxygen mix	11054-152	NITROGEN
NexAir LLC	NITROGEN OXYGEN MIX	nitrogen oxygen mix	12213-733	NITROGEN

Nitrogen-Oxygen Mix Excipient Strategy and Commercial Opportunities

Last updated: September 4, 2026

Nitrogen-oxygen mixtures are primarily medical gas products, not conventional drug formulations. The gases themselves are the active components, while the commercial protection typically resides in composition control, manufacturing, cylinder systems, delivery equipment, quality specifications, and narrowly defined clinical uses. A simple oxygen-nitrogen blend has limited composition-patent strength and generally does not support conventional excipient-based lifecycle management.

What is a nitrogen-oxygen mix used for?

A nitrogen-oxygen mix combines oxygen with nitrogen as the balance gas. Its clinical and industrial value depends on the oxygen concentration, delivery route, intended patient population, and delivery system.

Product category	Typical composition	Primary use	Commercial position
Medical air	Approximately 21% oxygen, balance primarily nitrogen	Ventilation, anesthesia, respiratory support	Established medical gas
Oxygen-enriched air	More than 21% oxygen, balance nitrogen	Respiratory support and oxygen delivery	Competes with oxygen and medical air
Controlled hypoxic mixture	Less than 21% oxygen, balance nitrogen	Research, altitude simulation, controlled respiratory applications	Specialized market
Custom oxygen-nitrogen blend	Concentration set by clinical or technical specification	Hospital, research, industrial or specialty use	Custom-manufactured product
Calibration or test gas	Certified oxygen concentration in nitrogen	Instrument calibration and quality control	Industrial gas rather than medicinal product

The product should not be treated as a conventional formulation containing an active pharmaceutical ingredient and inactive excipients. In a medicinal gas, oxygen and nitrogen are components of the administered gas stream. Nitrogen may act as a diluent or balance gas, but it is not an excipient in the conventional tablet, injectable or liquid formulation sense.

What excipients are appropriate for a nitrogen-oxygen mixture?

Conventional excipients are generally unnecessary

A nitrogen-oxygen gas mixture normally contains no excipient. The formulation is defined by:

• Oxygen concentration;
• Nitrogen concentration;
• Water content;
• Specified impurity limits;
• Pressure and fill volume;
• Container and valve configuration;
• Delivery concentration at the patient interface.

Adding conventional excipients would usually be inappropriate. Liquids, stabilizers, preservatives and surfactants can create toxicity, contamination, flammability or device-compatibility risks.

The most commercially relevant "inactive" formulation controls are therefore process and packaging specifications rather than excipient selection.

Recommended quality attributes

A development specification should address the following attributes:

Quality attribute	Strategic purpose
Oxygen assay	Confirms the delivered therapeutic or technical concentration
Nitrogen assay	Confirms balance-gas composition
Water content	Limits corrosion, condensation and microbial risk
Carbon monoxide and carbon dioxide	Controls toxic or physiologically relevant impurities
Hydrocarbon and oil contamination	Reduces fire and combustion risk
Particulate matter	Controls cylinder and valve contamination
Odor and appearance	Detects contamination or degradation
Fill pressure	Controls dose duration and delivery performance
Cylinder material compatibility	Supports repeated filling and transport
Valve outlet and connector standard	Prevents misconnections

The product should be manufactured under medical-gas quality systems where the intended use is medicinal. FDA requirements for medical gases address identity, purity, labeling, containers and manufacturing controls. The European Pharmacopoeia and national medicinal-gas requirements apply in European markets (U.S. Food and Drug Administration [FDA], 2018; European Directorate for the Quality of Medicines & HealthCare, n.d.).

How should the excipient strategy differ by product type?

Hospital respiratory product

For a hospital product, the formulation strategy should prioritize exact oxygen concentration, compatibility with ventilators and anesthesia systems, and reliable delivery through pipeline or cylinder infrastructure. A standard medical-air composition may have limited differentiation, while a validated custom concentration could support niche clinical applications.

The product dossier should include:

• Gas composition and assay method;
• Cylinder filling and blending method;
• Homogeneity validation;
• Stability during storage;
• Compatibility with regulators and flowmeters;
• Connection standards;
• Labeling for oxygen concentration and intended use;
• Controls for cross-contamination between oxygen and nitrogen service.

Home-care product

Home-care commercialization requires a different strategy. The gas mixture must work with portable cylinders, concentrators, regulators or demand valves. Product value comes from portability, duration of use, delivery accuracy and reimbursement status.

A nitrogen-oxygen mixture has a higher practical barrier in the home than ordinary oxygen because many existing devices are configured for oxygen-only delivery or ambient air. The company would need to validate the mixture with the intended device and manage user error, misconnection and incorrect flow settings.

Research and controlled-hypoxia product

A low-oxygen nitrogen mixture may be used in research, altitude simulation or controlled environmental applications. The commercial opportunity is stronger when the product is sold with a validated system that controls oxygen concentration, flow, monitoring and alarms.

The product should not rely solely on a gas composition claim. A more defensible package may include:

• Certified blend;
• Closed-loop oxygen monitoring;
• Automatic shutoff;
• Sensor calibration;
• Environmental chamber or breathing apparatus;
• Software controlling concentration and exposure duration.

Industrial and calibration product

For calibration, the critical attributes are certified concentration, traceability, uncertainty, cylinder stability and documentation. This segment is governed more by metrology and industrial gas standards than by medicinal-product rules. A medicinal claim should not be used for a product marketed only for instrument calibration.

What patents protect a nitrogen-oxygen mixture?

A simple nitrogen-oxygen composition is usually difficult to protect broadly. Oxygen and nitrogen are established substances, and many concentration ranges are likely to face novelty and obviousness challenges. Patent value is more likely to arise from the following claim categories:

Patent category	Potential strength	Commercial relevance
Narrow concentration range	Low to moderate	Supports a defined clinical or technical use
Therapeutic method of use	Moderate	Can protect a specific patient group or treatment protocol
Gas blending process	Moderate	Protects accuracy, homogeneity or continuous production
Cylinder and valve system	Moderate to strong	Can create switching and compatibility barriers
Delivery device	Stronger	Protects controlled administration and safety features
Closed-loop monitoring	Stronger	Protects sensor-based concentration control
Manufacturing and filling method	Moderate	Limits contamination and improves production efficiency
Packaging and logistics	Low to moderate	Can reduce leakage, degradation or transport risk

The strongest strategy is usually a layered portfolio combining composition, use, delivery and manufacturing claims. A composition-only patent is unlikely to provide durable exclusivity for a conventional blend.

How strong is the patent estate for a nitrogen-oxygen mixture?

The patent estate is generally weak for the gases themselves and stronger for the delivery platform.

A practical strength assessment is:

• Composition: weak if the claims cover ordinary oxygen and nitrogen ranges.
• Specific clinical use: moderate if supported by controlled clinical data.
• Delivery system: moderate to strong where the system solves oxygen-concentration, safety or portability problems.
• Manufacturing process: moderate where blending accuracy, contamination control or continuous production is difficult to replicate.
• Device integration: strong if the product requires proprietary hardware, software or consumables.

Patent claims should avoid relying on broad terms such as "oxygen-enriched gas" or "nitrogen-diluted oxygen" without measurable concentration, flow, exposure or outcome limitations. Competitors may design around those claims by changing concentration, flow rate, delivery route or control logic.

What is the FDA regulatory status of nitrogen-oxygen mixtures?

In the United States, medicinal gases are regulated as drugs. FDA identifies medical gases as a distinct regulatory category and has issued guidance covering manufacturing, labeling, containers, closures and current good manufacturing practice expectations (FDA, 2018).

The regulatory path depends on the product's intended use:

Intended use	Likely regulatory treatment
Respiratory therapy	Drug or medical gas product
Anesthesia or ventilation	Drug and device interfaces
Home-care therapeutic use	Drug product with delivery-device controls
Research exposure without therapeutic claims	May fall outside medicinal-drug positioning, depending on claims
Instrument calibration	Industrial or analytical gas
Food packaging or welding	Industrial gas

A commercial sponsor must align the composition, label, manufacturing site, cylinder, valve, delivery equipment and clinical claims. A custom oxygen-nitrogen mixture marketed for a new therapeutic indication may require a more substantial FDA submission than a standardized designated medical gas.

What is the Orange Book status?

A nitrogen-oxygen mixture is not expected to have a conventional Orange Book patent profile unless it is marketed under an approved application for which patent information is eligible for listing. Simple medical-gas products generally do not produce the type of Orange Book-listed formulation and method-of-use estate associated with small-molecule prescription drugs.

The absence of an Orange Book listing does not eliminate patent risk. Relevant rights may still cover:

• Gas blending;
• Cylinder filling;
• Delivery equipment;
• Monitoring systems;
• Clinical methods;
• Manufacturing software;
• Device-drug combinations.

When does nitrogen-oxygen mix lose exclusivity?

There is no single exclusivity date for the product category. Exclusivity depends on the sponsor's regulatory approval, patents and device rights.

Exclusivity element	Typical issue
Regulatory exclusivity	Depends on the approval pathway and product designation
Composition patent	Expires 20 years from the effective nonprovisional filing date in the U.S., subject to adjustments
Method-of-use patent	Same statutory term, subject to terminal disclaimers and adjustments
Device patent	Commonly 20 years from the relevant U.S. filing date
Trade secret	Can continue while the process remains confidential
Contractual exclusivity	Depends on supply, distribution or licensing terms

A conventional nitrogen-oxygen mixture has no category-wide exclusivity period. Generic or competing entry is principally controlled by regulatory compliance, supply reliability, hospital contracts, installed equipment and reimbursement.

Are Paragraph IV challenges relevant?

Paragraph IV litigation is less central than it is for branded tablets or injectable drugs. A competitor can challenge an eligible Orange Book-listed patent through an abbreviated application only if the reference product and listed patents support that pathway.

For a nitrogen-oxygen product, competitive entry is more likely to occur through:

• A separate medical-gas application;
• A different concentration;
• A different cylinder or valve configuration;
• A device-drug combination;
• A hospital-supply contract;
• A nonmedicinal research or industrial product.

Where an approved application has eligible listed patents, a Paragraph IV certification could arise. In the broader medical-gas market, patent disputes are more likely to involve device infringement, trade secrets, supply agreements or regulatory misbranding.

What formulation and method-of-use patents are commercially valuable?

The most valuable claims would connect a defined gas composition with a measurable delivery or clinical result.

Potential formulation claims include:

1. A defined oxygen range with nitrogen as the balance gas.
2. Maximum water and impurity limits.
3. A specific pressure and fill-volume range.
4. A composition stable over a stated storage period.
5. A composition packaged in a specified cylinder and valve system.

Potential method-of-use claims include:

1. Controlled delivery to a defined patient group.
2. Titration based on oxygen saturation or another monitored parameter.
3. Use with a specific ventilator or breathing circuit.
4. Delivery for a defined exposure duration.
5. Use in a controlled hypoxia or altitude-simulation protocol.

Clinical-use patents require credible supporting data. A broad claim covering any administration of oxygen diluted with nitrogen would face substantial validity and design-around risks.

What commercial opportunities exist for nitrogen-oxygen mixtures?

Hospital and critical-care supply

The largest established opportunity is hospital respiratory infrastructure. A differentiated blend could target institutions that need controlled gas concentrations, specialized ventilation protocols or customized research services. The barriers are procurement qualification, pipeline compatibility and supply continuity.

Home respiratory care

Portable delivery creates an opportunity if the mixture supports a clear clinical use and offers a measurable advantage over oxygen concentrators or medical air. The business case depends on device integration, refill logistics and payer coverage.

Controlled-hypoxia systems

Research institutions, sports-science laboratories, sleep centers and altitude-training facilities may purchase certified blends with monitoring systems. The strongest model is a system sale or recurring service contract rather than commodity gas sales.

Pharmaceutical and biotechnology manufacturing

Nitrogen and oxygen mixtures can support cell-culture, bioprocessing and controlled-atmosphere applications. The commercial value lies in validated gas quality, continuous supply, analytics and process integration. These uses may be regulated under industrial or bioprocess standards rather than as medicinal products.

Calibration and sensor validation

Certified oxygen-in-nitrogen mixtures are used to calibrate oxygen analyzers, ventilators and environmental monitoring equipment. This segment can generate recurring revenue through cylinder exchange, certification and recalibration services.

Which companies are competing in the nitrogen-oxygen gas market?

Competition is likely to come from large industrial-gas companies, regional medical-gas suppliers, hospital gas distributors and device manufacturers. The relevant competitive set includes suppliers with capabilities in:

• Medical oxygen and medical air;
• Nitrogen generation and purification;
• Cylinder filling;
• Bulk and pipeline distribution;
• Gas blending;
• Respiratory delivery devices;
• Oxygen monitoring;
• Hospital service and maintenance.

A new entrant is unlikely to compete effectively on gas molecules alone. Differentiation should focus on a protected delivery platform, a validated clinical protocol, superior logistics or an integrated monitoring service.

What manufacturing and intellectual-property barriers exist?

Manufacturing barriers are operational rather than chemical. They include:

• Accurate blending across the target concentration range;
• Prevention of oxygen-service contamination;
• Cylinder segregation and traceability;
• Valve compatibility;
• Leak testing;
• Homogeneity validation;
• Fill-pressure control;
• Calibration of analyzers;
• Distribution under temperature and transport constraints;
• Qualification of contract fillers.

The most defensible trade secrets may concern blending controls, filling sequences, sensor calibration, cylinder management and quality-release analytics. These processes can complement patents because they are difficult to reverse engineer from the finished gas.

What licensing deals and settlement risks should be evaluated?

Licensing opportunities are most relevant to:

• Proprietary gas-mixing systems;
• Portable delivery devices;
• Oxygen sensors;
• Closed-loop control software;
• Hospital pipeline access;
• Cylinder fleets;
• Clinical protocols;
• Distribution networks.

Settlement agreements may become relevant if a sponsor asserts patents against a competing delivery device or gas-blending process. Traditional generic settlements are less likely unless the product has an approved application with listed patents and a commercially important indication.

How does nitrogen-oxygen mix compare with oxygen and medical air?

Factor	Nitrogen-oxygen mix	Medical oxygen	Medical air
Active gas	Oxygen plus nitrogen	Oxygen	Approximately 21% oxygen with nitrogen balance
Composition flexibility	High	Low	Low
Composition patentability	Limited for ordinary ranges	Limited	Limited
Delivery complexity	Moderate to high	Low to moderate	Moderate
Device dependence	Often high	Moderate	Moderate
Main differentiation	Concentration and control	Purity, supply and delivery	Reliability and infrastructure
Regulatory complexity	Depends on claims and ratio	Established	Established
Commercial moat	System and workflow	Supply network	Hospital infrastructure

Key Takeaways

• Nitrogen-oxygen mixtures generally have no conventional excipients. Oxygen and nitrogen are the administered gas components.
• Product value depends on composition accuracy, purity, cylinder systems and delivery control.
• Broad composition patents are usually weak for established oxygen-nitrogen ranges.
• The strongest intellectual property is likely to cover delivery devices, monitoring, blending methods, manufacturing controls and specific clinical protocols.
• FDA treatment depends on intended use, labeling, concentration and delivery system.
• Orange Book and Paragraph IV issues are less central than in conventional small-molecule drug markets.
• Commercial opportunities are strongest in integrated hospital systems, controlled-hypoxia platforms, calibration gases and validated bioprocess applications.
• Generic entry risk is driven by regulatory compliance, equipment compatibility, supply contracts and logistics rather than molecule-level patent exclusivity.
• A defensible launch strategy should combine gas supply with proprietary hardware, monitoring, software, quality certification or a validated method of use.

FAQs

Is nitrogen an excipient in a medical oxygen product?

Usually not. Nitrogen is the balance gas or diluent component of the administered mixture. It is better characterized as a formulation component than as a conventional pharmaceutical excipient.

Can a nitrogen-oxygen mixture receive orphan-drug exclusivity?

Only if the product satisfies the applicable orphan-drug criteria for a specific rare disease or condition and obtains the required regulatory designation and approval. The gas mixture alone does not create orphan-drug eligibility.

Can a nitrogen-oxygen mixture be sold without a proprietary patent?

Yes. Medical gases can compete through regulatory compliance, manufacturing quality, distribution, hospital contracts and device integration. Patent ownership is not required to market an otherwise authorized product.

What is the main safety issue in nitrogen-oxygen gas manufacturing?

The main risks include incorrect concentration, oxygen-service contamination, cylinder misconnection, leakage, pressure failure and delivery-device malfunction. Quality systems must control both gas composition and the complete delivery pathway.

Is a nitrogen-oxygen mixture a biosimilar product?

No. Biosimilar rules apply to biological products. A nitrogen-oxygen mixture is a chemical gas product and does not use the biosimilar regulatory pathway.

References

1. European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia: Medical gases and related monographs. Council of Europe.

2. U.S. Food and Drug Administration. (2018). Medical gas containers and closures: Current good manufacturing practice requirements. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2023). Medical gases: Regulatory information and guidance. U.S. Department of Health and Human Services.

4. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Medical gases and compressed gases. United States Pharmacopeial Convention.

5. World Health Organization. (2017). WHO technical specifications for medical oxygen systems. World Health Organization.